Efectividad de la glucosa Tetrasacarido (glc4) como Biomarcador de apoyo diagnóstico de la Enfermedad de Pompe. Revisión sistemática de la literatura

dc.contributorDurán-Torres, Felipe
dc.creatorRodríguez Lara, Wendy Alejandra
dc.creatorMora Rincón, Yenny Roxana
dc.date.accessioned2021-10-26T16:45:49Z
dc.date.accessioned2022-09-22T14:56:17Z
dc.date.available2021-10-26T16:45:49Z
dc.date.available2022-09-22T14:56:17Z
dc.date.created2021-10-26T16:45:49Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/32838
dc.identifierhttps://doi.org/10.48713/10336_32838
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3443531
dc.description.abstractObjectives: To analyze the effectiveness of Glc4 as a diagnostic support biomarker for Pompe disease. Introduction: Pompe disease is a neuromuscular disorder, progressive and frequently fatal, caused by the mutation in the gene that produces the acid lysosomal alpha-glucosidase enzyme, whose action is to degrade glycogen. There is a need to standardize a biomarker such as Glc4 that allows, quickly and practically, to determine the deficiency of the enzyme. Methods: A systematic search was carried out in the following databases: Medline (Pubmed), ScienceDirect, Cochrane Library, Clinicaltrials.gov and Google Scholar. The studies were screened by title and abstract to subsequently perform a full text screening based on selection criteria. A qualitative synthesis was performed with the included studies. Results: 18 studies met the selection criteria, the synthesis of which was qualitative given the high methodological heterogeneity between studies, with 386 participants (63.99% IOPD and 55.06 LOPD), 53.57% had elevated baseline Glc4 levels. Conclusions: Glc4 can be used as a diagnostic support biomarker of Pompe disease, since it has a directly proportional relationship with the increase in glycogen, however, in patients with early presentation or mild affectations it can be complemented with genetic tests, of imaging and physiatry.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherEspecialización en Epidemiología
dc.publisherEscuela de Medicina y Ciencias de la Salud
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.source1. Kohler L, Puertollano R, Raben N. Pompe Disease: From Basic Science to Therapy. Neurotherapeutics. 2018;15(4):928–42. 2. MINSAL 2018. EN LA EVIDENCIA DISPONIBLE Condición de Salud : Enfermedad de Pompe Tecnología Sanitaria Evaluada : Alglucosidasa Alfa para la deficiencia de Maltasa Ácida o Glucogenosis Tipo II o Enfermedad de Pompe Sistema de Protección Financiera para Diagnósticos y T. 3. Moreno-Medinilla E, Berzosa-López R, Dolores Mora-Ramírez M, Blasco-Alonso J, Martínez-Antón J. Variabilidad en la presentación clínica de la enfermedad de pompe infantil: Presentación de dos casos y respuesta al tratamiento con enzima recombinante humana. Rev Neurol. 2014;59(11):503–7. 4. Barba-Romero MA, Barrot E, Bautista-Lorite J, Gutiérrez-Rivas E, Illa I, Jiménez LM, et al. Guía clínica de la enfermedad de pompe de inicio tardío. Rev Neurol. 2012;54(8):497–507. 5. Bravo-Oro A, de la Fuente-Cortez B, Molina-García A, Romero-Díaz V, Rodríguez-Leyva I, Esmer-Sánchez MC, et al. [Diagnosis and treatment of Pompe disease]. | Diagnóstico y tratamiento en la enfermedad de Pompe. Rev Med Inst Mex Seguro Soc [Internet]. 2013;51(5). Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84908393119&partnerID=MN8TOARS 6. Zhang XT, Ren WD. Research advances in the diagnosis and treatment of Pompe disease. Chinese J Contemp Pediatr. 2018;20(7):588–93. 7. Ridaura-Sanz, Cecilia; de León-Bojorge, Beatriz; Belmont-Martínez, Leticia; Vela-Amieva M. Enfermedad de Pompe forma infantil (glucogenosis tipo II). Informe de dos casos en niños mexicanos descubiertos por autopsia. Acta Pediátrica México. 2009;30(3):142–7. 8. Bobillo Lobato J, Durán Parejo P, Tejero Díez P, Jiménez Jiménez LM. Glucosa tetrasacárido como biomarcador diagnóstico de la enfermedad de Pompe: Estudio en 35 pacientes. Med Clin (Barc). 2013;141(3):106–10. 9. de León-Ojeda NE, Seiglie-Díaz F, García-García A, Tápanes-Daumy H, Cañizares CV, Sánchez TA, et al. Diagnóstico y tratamiento de la enfermedad de Pompe. Rev Cubana Pediatr. 2016;88(3):375–87. 10. Bobillo Lobato J, Jiménez Hidalgo M, Jiménez Jiménez L. Biomarkers in Lysosomal Storage Diseases. Diseases. 2016;4(4):40. 11. Carretero Colomer M. Enfermedad de Pompe: nuevas perspectivas terapéuticas. Offarm Farm y Soc. 2007;26(11):84–6. 12. Richard E, Douillard-Guilloux G, Caillaud C. New insights into therapeutic options for Pompe disease. IUBMB Life. 2011;63(11):979–86. 13. Hobson-Webb LD, DeArmey S, Kishnani PS. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol [Internet]. 2011;122(11):2312–7. Available from: http://dx.doi.org/10.1016/j.clinph.2011.04.016 14. Dasouki M, Jawdat O, Almadhoun O, Pasnoor M, McVey AL, Abuzinadah A, et al. Pompe disease: Literature review and case series. Neurol Clin [Internet]. 2014;32(3):751–76. Available from: http://dx.doi.org/10.1016/j.ncl.2014.04.010 15. Hospital Maternoinfantil U de B. Enfermedad de pompe o glucogenosis tipo II. Guía Metabólica. 2015;4. 16. Piraud M, Pettazzoni M, de Antonio M, Vianey-Saban C, Froissart R, Chabrol B, et al. Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort. Mol Genet Metab Reports [Internet]. 2020;23(March):100583. Available from: https://doi.org/10.1016/j.ymgmr.2020.100583 17. Alonso-Pérez J, Segovia S, Domínguez-González C, Olivé M, Mendoza Grimón MD, Fernández-Torrón R, et al. Spanish Pompe registry: Baseline characteristics of first 49 patients with adult onset of Pompe disease. Med Clin (Barc). 2020;154(3):80–5. 18. Katzin LW, Amato AA. Pompe disease: A review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. J Clin Neuromuscul Dis. 2008;9(4):421–31. 19. Chien YH, Hwu WL, Lee NC. Pompe disease: Early diagnosis and early treatment make a difference. Pediatr Neonatol [Internet]. 2013;54(4):219–27. Available from: http://dx.doi.org/10.1016/j.pedneo.2013.03.009 20. van der Beek NA, Hagemans ML, van der Ploeg AT, van Doorn PA, Merkies IS. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord [Internet]. 2013;23(3):256–64. Available from: http://dx.doi.org/10.1016/j.nmd.2012.10.024 21. Aerts JMFG, Kallemeijn WW, Wegdam W, Joao Ferraz M, Van Breemen MJ, Dekker N, et al. Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011;34(3):605–19. 22. Manwaring V, Prunty H, Bainbridge K, Burke D, Finnegan N, Franses R, et al. Urine analysis of glucose tetrasaccharide by HPLC; A useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inherit Metab Dis. 2012;35(2):311–6. 23. Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, et al. Assessing disease severity in Pompe disease: The roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet Part C Semin Med Genet. 2012;160 C(1):50–8. 24. Philip L P, Keith H, J C, Colleen L M, Yuezhou Y, Donald T. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening. JIMD Rep. 2012;4:113–6. 25. Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. Newborn screening for pompe disease: Synthesis of the evidence and development of screening recommendations. Pediatrics. 2007;120(5). 26. Kishnani PS, Beckemeyer AA, Mendelsohn NJ. The new era of Pompe disease: Advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet Part C Semin Med Genet. 2012;160 C(1):1–7. 27. Cousens LP, Mingozzi F, Marel S Van Der, Su Y, Garman R, Ferreira V, et al. Teaching tolerance: New approaches to enzyme replacement therapy for pompe disease. Hum Vaccines Immunother. 2012;8(10):1459–64. 28. Do H V., Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. 2019;7(13):291–291. 29. Sluiter W, Van Den Bosch JC, Goudriaan DA, Van Gelder CM, De Vries JM, Huijmans JGM, et al. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in pompe disease and other glycogen storage diseases. Clin Chem. 2012;58(7):1139–47. 30. An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corz D, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab. 2005;85(4):247–54. 31. Chien YH, Tsai WH, Chang CL, Chiu PC, Chou YY, Tsai FJ, et al. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences. Mol Genet Metab Reports [Internet]. 2020;23(April):100591. Available from: https://doi.org/10.1016/j.ymgmr.2020.100591 32. Pollissard L, DasMahapatra P, Baranowski E, Haack KA, Zhou T, Thibault N, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe. Neuromuscul Disord. 2021;31(March 2010):S111. 33. Li C, Desai AK, Gupta P, Dempsey K, Bhambhani V, Hopkin RJ, et al. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med [Internet]. 2021;23(5):845–55. Available from: http://dx.doi.org/10.1038/s41436-020-01080-y 34. Saville JT, Fuller M. Experience with the urinary tetrasaccharide metabolite for pompe disease in the diagnostic laboratory. Metabolites. 2021;11(7). 35. Prater SN, Banugaria SG, Dearmey SM, Botha EG, Stege EM, Case LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Vol. 14, Genetics in Medicine. 2012. p. 800–10. 36. Mugdha V. Rairikar, MBBS, DCH1,*, Laura E. Case, DPT, PCS3,*, Lauren A. Bailey, MS, CGC1, Zoheb B. Kazi, MBBS1, Ankit K. Desai, MBBS1, Kathryn L. Berrier, MS, CGC1, Julie Coats, MPT, C/NDT2, Rachel Gandy, DPT, PCS2, Rebecca Quinones, DPT, PCS2, and Priya M. HHS Public Access Author manuscript Mol Genet Metab. Author manuscript; available in PMC 2018 November 01. Published in final edited form as: Mol Genet Metab. 2017 November ; 122(3): 99–107. doi:10.1016/j.ymgme.2017.09.008. Insight into the phenotype of i. Physiol Behav. 2017;176(12):139–48. 37. Khan AA, Case LE, Herbert M, DeArmey S, Jones H, Crisp K, et al. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet Med. 2020;22(5):898–907.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectGlucogenosis tipo II
dc.subjectSensibilidad y especificidad de Glc4
dc.subjectBiomarcadores
dc.subjectDepósito lisosomal
dc.titleEfectividad de la glucosa Tetrasacarido (glc4) como Biomarcador de apoyo diagnóstico de la Enfermedad de Pompe. Revisión sistemática de la literatura
dc.typebachelorThesis


Este ítem pertenece a la siguiente institución